214870 — NewGLab Pharma Co Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -122.51% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 95,819.85 | 54,416.7 | 29,353.91 | 21,710.75 | 12,621.17 | n/a | n/a | -7.5% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
NewGLab Pharma Co Ltd, formerly NewGLab Co Ltd, is a company mainly engaged in the manufacturing and sale of closed-circuit television (CCTV) cameras. The Company's product portfolio consists of general analog cameras that used for CCTVs, high definition (HD) analog cameras, HD-serial digital interface (SDI) cameras, extend (EX)-SDI cameras, internet protocol (IP) cameras that used for network CCTVs, digital video recorders (DVRs) that used for image storage devices, network video recorders (NVRs) and others. In addition, the Company is involved in the business of 5G smartphone distribution. The Company distributes its products within domestic market and to overseas markets.
Directors
- Dae Wu Park CEO (50)
- Han Su Lee OTH (46)
- Dong Hui Liu OTH (44)
- Hyo Anh Sung OTH (53)
- Hudson Chang DRC (44)
- Hui Wun Cho DRC (36)
- Dae Hye Kim DRC (36)
- Yeong Yil Kim DRC (41)
- Byeong Gi Oh DRC (53)
- Rui Rui Han NID (37)
- Jae Sang Jung NID (45)
- Byeong Jun Kim NID
- Jae Seok Yim NID (51)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 24th, 2004
- Public Since
- October 13th, 2015
- No. of Shareholders
- 33,100
- No. of Employees
- 172
- Sector
- Computers, Phones & Household Electronics
- Industry
- Technology
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 46,796,106
- Address
- 23, Sinheung-ro 362beon-gil, BUCHEON, 14491
- Web
- http://newglab.com
- Phone
- +82 326837903
- Auditors
- DaeSung SamKyung Accounting Corporation
Upcoming Events for 214870
Similar to 214870
Abko Co
Korea Exchange - KOSDAQ
Atec Co
Korea Exchange - KOSDAQ
Atec Mobility Co
Korea Exchange - KOSDAQ
Cots Technology Co
Korea Exchange - KOSDAQ
Digital Graphics
Korea Exchange - KOSDAQ
FAQ
As of Today at 19:15 UTC, shares in NewGLab Pharma Co are trading at KR₩1,383. This share price information is delayed by 15 minutes.
Shares in NewGLab Pharma Co last closed at KR₩1,383 and the price had moved by -78.58% over the past 365 days. In terms of relative price strength the NewGLab Pharma Co share price has underperformed the FTSE Developed Asia Pacific Index by -77.65% over the past year.
There is no consensus recommendation for this security.
NewGLab Pharma Co does not currently pay a dividend.
NewGLab Pharma Co does not currently pay a dividend.
NewGLab Pharma Co does not currently pay a dividend.
To buy shares in NewGLab Pharma Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩1,383, shares in NewGLab Pharma Co had a market capitalisation of .
Here are the trading details for NewGLab Pharma Co:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 214870
Based on an overall assessment of its quality, value and momentum NewGLab Pharma Co is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like NewGLab Pharma Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -84.8%.
As of the last closing price of KR₩1,383, shares in NewGLab Pharma Co were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The NewGLab Pharma Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩1,383.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
NewGLab Pharma Co's management team is headed by:
- Dae Wu Park - CEO
- Han Su Lee - OTH
- Dong Hui Liu - OTH
- Hyo Anh Sung - OTH
- Hudson Chang - DRC
- Hui Wun Cho - DRC
- Dae Hye Kim - DRC
- Yeong Yil Kim - DRC
- Byeong Gi Oh - DRC
- Rui Rui Han - NID
- Jae Sang Jung - NID
- Byeong Jun Kim - NID
- Jae Seok Yim - NID